Abstract
It has been postulated that cirrhosis-related lung vasodilatation and the subsequent hepatopulmonary syndrome are partly explained by an increased estradiol level through an enhanced endothelial formation of nitric oxide (NO). In this study, we assessed whether the oestrogen receptor antagonist fulvestrant (F) improves cirrhosis-related lung abnormalities. Cirrhosis was induced in rats by chronic bile duct ligation (CBDL). Four groups were studied: CBDL, CBDL+F, sham, and sham+F. Histological, immunohistochemical, and Western blot analyses were performed on lung samples. In the lung, the endothelial NO synthase and the nitrotyrosine protein expressions were increased in CBDL as compared to sham rats. Both parameters were significantly reduced by fulvestrant in the CBDL rats. Surprisingly, the level of pVASP (an indirect marker of NO formation and action) was decreased in CBDL rats, and fulvestrant had no effect on this parameter. The level of the vascular endothelial growth factor, the diameter of small lung vessels, and the number of macrophages were increased in CBDL lungs in comparison with sham lungs, and these parameters were unaffected by fulvestrant treatment. In conclusion, fulvestrant may not be relevant to improve lun...Continue Reading
References
Mar 1, 1994·Journal of Hepatology·J GuéchotR Poupon
Mar 1, 1996·The European Respiratory Journal·F ChabotA T Dinh-Xuan
Sep 12, 1998·Annals of Internal Medicine·G RollaC Bucca
Nov 14, 2000·Annals of Internal Medicine·P SchenkC Müller
Aug 18, 2001·Journal of Endocrinological Investigation·R AllerR Bárcena
Sep 11, 2001·American Journal of Respiratory and Critical Care Medicine·H NunesP Hervé
Mar 12, 2002·Journal of Endocrinological Investigation·R AllerD A de Luis
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jong S KangKyu-Hwan Yang
Jul 13, 2002·American Journal of Physiology. Lung Cellular and Molecular Physiology·Ethan P CarterIvan F McMurtry
Dec 25, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Miguel R ArguedasMichael B Fallon
Apr 10, 2003·Biochemical and Biophysical Research Communications·Ho Jin YouHye Gwang Jeong
Jul 11, 2003·Lancet·L BrussinoG Rolla
Nov 5, 2003·Gastroenterology·Junlan ZhangMichael B Fallon
Jun 5, 2004·The European Respiratory Journal·B SztrymfP Hervé
Jun 9, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yiqun LingMichael B Fallon
Nov 2, 2004·The European Respiratory Journal·R Rodríguez-RoisinUNKNOWN ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee
Aug 16, 2005·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Serdar YolLema Tavlı
Sep 22, 2005·Journal of Gastroenterology and Hepatology·Benjamin SztrymfPhilippe Herve
Apr 22, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Federico P GómezRobert Rodríguez-Roisin
May 30, 2008·The New England Journal of Medicine·Roberto Rodríguez-Roisin, Michael J Krowka
Dec 27, 2008·Gastroenterology·Junlan ZhangMichael B Fallon
Nov 3, 2009·Gastroenterology·Stéphanie Dal-RosValérie B Schini-Kerth
Mar 5, 2010·Fundamental & Clinical Pharmacology·Cristiana VitaleSergio Chierchia
Mar 30, 2010·Gastroenterology·Kari E RobertsUNKNOWN Pulmonary Vascular Complications of Liver Disease Study Group
Dec 15, 2010·American Journal of Respiratory and Critical Care Medicine·Thenappan ThenappanStephen L Archer
Apr 13, 2011·Fundamental & Clinical Pharmacology·S IlavenilS Ravikumar
Jan 4, 2012·Fundamental & Clinical Pharmacology·Marina Galicia-MorenoPablo Muriel
Oct 10, 2012·Clinical Science·Ching-Chih ChangShou-Dong Lee